cqp 201-403 has been researched along with Hyperprolactinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brownell, J; Rolland, R; van der Heijden, PF | 1 |
| Brownell, J; Halse, J; Hanssen, LE; Jervell, J; Reinlie, S; Stokke, KT; Stray-Pedersen, S | 1 |
2 trial(s) available for cqp 201-403 and Hyperprolactinemia
| Article | Year |
|---|---|
Prolactin suppressant effect of CQP 201-403, a new dopamine agonist, in hyperprolactinemic women.
Topics: Clinical Trials as Topic; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Hormones; Humans; Hyperprolactinemia; Prolactin; Random Allocation | 1987 |
CQP 201-403, a new dopamine agonist in the treatment of hyperprolactinemia.
Topics: Adult; Clinical Trials as Topic; Ergolines; Fasting; Female; Humans; Hyperprolactinemia; Prolactin | 1988 |